INmune Bio, Inc. (NASDAQ:INMB) Receives $21.00 Consensus Price Target from Analysts
Shares of INmune Bio, Inc. (NASDAQ:INMB – Get Free Report) have been assigned a consensus recommendation of “Buy” from the six ratings firms that are presently covering the company, MarketBeat.com reports. Five research analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average […]
Shares of INmune Bio, Inc. (NASDAQ:INMB – Get Free Report) have been assigned a consensus recommendation of “Buy” from the six ratings firms that are presently covering the company, MarketBeat.com reports. Five research analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average […]
